Stock Financial Ratios, Dividends, Split History

TDG / Transdigm Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price337.19
Volume323,400.00
Market Cap ($M)17,065.86
Enterprise Value ($M)27,724.75
Book Value ($M)-2,309.34
Book Value / Share-44.05
Price / Book-6.56
NCAV ($M)-10,233.91
NCAV / Share-195.19
Price / NCAV-1.73
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 52,517,000
Common Shares Outstanding 51,959,702
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.07
Return on Assets (ROA)0.06
Return on Equity (ROE)-0.92
Balance Sheet (mrq) ($M)
Assets10,394.68
Liabilities12,704.01
Quick Ratio2.09
Current Ratio3.04
Income Statement (mra) ($M)
Sales Revenue Net3,504,286,000.00
Operating Income1,479.83
Net Income596.89
Earnings Per Share Basic And Diluted7.88
Cash Flow Statement (mra) ($M)
Cash From Operations788.73
Cash from Investing-287.00
Cash from Financing788.73
Identifiers and Descriptors
CUSIP893641100
Central Index Key (CIK)1260221
Related CUSIPS
893641950 089364110 893641900

Split History

Stock splits are used by Transdigm Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Transdigm (TDG) Up 6% Since Earnings Report: Can It Continue?

2018-05-31 zacks
It has been about a month since the last earnings report for Transdigm Group Incorporated (TDG - Free Report) . Shares have added about 6% in that time frame. (21-0)

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

2018-05-29 seekingalpha
Wallace Weitz's 13F portfolio value decreased marginally from $2.40B to $2.37B. The number of positions decreased from 77 to 75. (812-1)

Here's Why Adding TransDigm to Your Portfolio Makes Sense

2018-05-28 zacks
TransDigm Group Incorporated (TDG - Free Report) managed to impress investors with its recent earnings streak as the company’s bottom line trumped estimates thrice in the trailing four quarters. We believe that the company’s strong operational efficiency, its solid portfolio of products as well as complementary acquisitions will continue to be key growth drivers, going forward. (8-0)

Is Guggenheim S&P 500 Equal Weight Industrials ETF (RGI) a Hot ETF Right Now?

2018-05-21 zacks
The Guggenheim S&P 500 Equal Weight Industrials ETF (RGI - Free Report) made its debut on 11/01/2006, and is a smart beta exchange traded fund that provides broad exposure to the Industrials ETFs category of the U.S. equity market. (7-0)

Is Guggenheim S&P 500 Equal Weight Industrials ETF (RGI) a Hot ETF Right Now?

2018-05-17 zacks
A smart beta exchange traded fund, the Guggenheim S&P 500 Equal Weight Industrials ETF (RGI - Free Report) debuted on 11/01/2006, and offers broad exposure to the Industrials ETFs category of the U.S. equity market. (5-0)

CUSIP: 893641100